Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study

INTRODUCTION: Patients with severe allergic asthma (SAA) are at risk of severe exacerbations. Omalizumab is recommended as an add-on treatment for patients with uncontrolled SAA, despite high-dose inhaled corticosteroids and long acting β(2)-agonist combination therapy (standard therapy). RELIEF was...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Ahmad, Mona, Borboa Olivares, Lilia Margarita, Cardoso, Alexandre Pinto, Djazmati, Wagih, Vinuesa, Miguel Angel, Domínguez, María de Jesús García, Neto, Alcindo Cerci, Gamboa, Luis Ugalde, Lee, Jason K., Pinho, Nadine, Tassinari, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156055/
https://www.ncbi.nlm.nih.gov/pubmed/37273950
http://dx.doi.org/10.2174/18743064-v16-e2206130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156055/
https://www.ncbi.nlm.nih.gov/pubmed/37273950
http://dx.doi.org/10.2174/18743064-v16-e2206130

Ejemplares similares